Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Daily Dose - Palatin, Marina Biotech, Vivus

|Includes: MRNA, Palatin Technologies, Inc (PTN), VVUS

The Nasdaq Biotech is roaring forward after a great prior week up 1.5% already today! Here are some highlights for the day.

Palatin PTN presented positive new data of Bremelanotide in Female Sexual Desire Disorder. Female Sexual Desire Disorder people!!!! Have you ever wished, hoped, dreamed that your wife, significant other, and/or girlfriend wanted to have sex with you more (or at all)? I'm shocked when I get together with my male compadres and hear how little they have sex with their wives. Well, now there's hope. Now there's Palatin and it's FSDD drug Bremelandotide! Need I say any more?

  1.1599       8,000 $1.2182 -$476.39 -4.88% $9,279.20
Marina Biotech MRNA is up over 16% today after receiving $6 million in financing. Marina was one of my sleeper picks back when it was under $.30 share and has been on a tear since. I sold my position and took profits a few weeks ago but I still think it's a great buy with a market cap of only $25 million, a great intellectual property portfolio focused on RNAi, and a vast number of partnerships including Roche, Novartis, ViThera, Pfizer, AstraZeneca, and a number of academic alliances. Now that they have some money, they should be able to realize the true potential of the company and it's IP assets. I may buy into the stock again in the coming days/weeks/months.

Vivus VVUS will announce financial results after the market closes today. What they need to announce is a freaking partnership with a big pharma to sell their obesity drug Qsymia in the United States. This is the typical story of a biotech that does a nice job developing a product and getting it approved by the FDA but then fails miserably because it attempts to transition into a commercial organization (see my recent concerns regarding Chelsea's recent drug approval). The good news is that they inked two partnerships, in the US and overseas, to sell it's erectile dysfunction drug Stendra late last year. That should bring in some much needed revenues but the big story remains Qsymia and the stock will suffer until a big pharma is secured.

  6.73       5,000 $9.9806 -$16,312.96 -32.65% $33,650.00

Disclosure: I am long VVUS, PTN.